英国药品和保健品监管局（MHRA）已正式批准Zapomeran（商品名Kostaive）mRNA新冠疫苗的紧急使用授权，该疫苗获准用于18岁及以上成年人群的主动免疫接种。此次批准标志着基于mRNA技术的新冠疫苗阵营再添重要力量，为应对持续演变的疫情提供了新的防控工具。
作为由Arcturus Therapeutics Ltd.（ARCT）研发的创新型疫苗，Zapomeran采用自扩增mRNA技术平台，具有单剂接种可能诱发强效免疫应答的潜力。监管机构基于临床试验数据认定，该疫苗对预防新冠病毒感染展现出良好的安全性与有效性特征。
此次获批将扩大英国疫苗接种计划的可选范围，为不同健康需求的成年人群提供更多免疫策略选择。随着变异毒株持续出现，新型疫苗的加入有望强化社会层面的免疫屏障建设。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.